Peptide guide
BPC-157: what it is and what the research actually shows
BPC-157 is a lab-made peptide copied from a fragment of a protein in human stomach fluid. Almost everything known about it comes from rats. A 2025 systematic review states plainly that no clinical safety data exist for it.
Byline: Mark Sommers, editor. Sources checked 08-26-2026. Every claim below links to its PubMed record or FDA page.
Quick facts
- What is in it
- One lab-made peptide of fifteen amino acids, copied from a fragment of a protein found in human stomach fluid. It is not a blend.
One molecule, not a blend. BPC-157 is one of the peptides sold together in blends such as KLOW and GLOW. The studies below are about BPC-157 tested on its own, not about any blend.
- Studied for
- Gut, tendon, ligament, muscle and bone healing, almost entirely in rats. In people, small uncontrolled reports looked at knee pain and stubborn bladder pain. A separate two-person pilot checked heart, liver, kidney, thyroid and blood sugar markers.
- Human evidence, part by part
- BPC-157Limited3 human studies found
- Approved by the FDA?
- Not an FDA-approved drug, and not approved by any regulator anywhere. BPC-157 appears on FDA's list of bulk drug substances that were nominated for compounding use and then withdrawn. See where it stands.
Benefits
- Evidence Improved healing of tendon, ligament, muscle and bone across 35 animal studies, per a 2025 review. PMID 40756949
- Evidence Most patients said they felt better months later in a 16-person case series for knee pain. PMID 34324435
- Evidence Women reported big improvement in stubborn bladder pain in a 12-person pilot study. PMID 39325560
- Evidence Sped tendon-cell growth and movement in a rat-tendon-cell dish study. PMID 21030672
- Suggested Discussed for gut, tendon, ligament, muscle and bone healing, based mostly on rat studies.
- Suggested Promoted for injury recovery in the popular 'Wolverine' stack with TB-500, a pairing never tested together.
- Suggested Discussed by online clinician commentary as a leading healing peptide despite thin human evidence.
Evidence items link to the study behind them. Suggested items are claims in circulation, not results.
Reported side effects
- A 2025 systematic review of 36 studies states plainly that no clinical safety data exist for BPC-157. PMID 40756949
- Animal studies show no harm across organs, per the same 2025 review, but human safety data is missing. PMID 40756949
- No biomarker changes appeared in a two-person pilot checking heart, liver, kidney, thyroid and blood sugar. PMID 40131143
- Has been on the World Anti-Doping Agency's prohibited list since 2022. PMID 40005999
- Is on FDA's list of bulk substances nominated for compounding, then withdrawn over safety concerns.
Safety, before anything else
A 2025 systematic review states plainly that no clinical safety data exist for BPC-157. The human reports that do exist are small, uncontrolled and mostly self-reported. BPC-157 is not approved by any regulator, is on FDA's list of bulk substances nominated for compounding and then withdrawn, and has been on the World Anti-Doping Agency prohibited list since 2022.
BPC-157
- Systematic review: animal studies show no harm across organs, but there is no human safety data. PMID 40756949
- No adverse events in a 12-person pilot. PMID 39325560
- Animal studies show no harm across organs; no human safety data. PMID 40756949
- Placed on the World Anti-Doping Agency prohibited list in 2022; unapproved by regulators. PMID 40005999
- No biomarker changes in a two-person pilot. PMID 40131143
We do not publish amounts or schedules of our own, on any page. The clinician commentary lower on this page quotes amounts that named clinicians state on camera, labeled and linked to the source video. Those are their words, not our guidance. Why we draw that line.
How to read the grades
Each study gets a tag. Cells in a dish means it never touched a living animal. Animals means mice or rats, usually. Small human study means a handful of people with no comparison group. Human trial means people were randomly split into treated and untreated groups, which is the only kind that can show an effect is real. Review and Systematic review sum up other studies. The full rule is on How we check.
BPC-157
A lab-made peptide (15 amino acids) copied from a piece of a protein in human stomach fluid. Studied mostly in rats for gut and tendon healing.
Human evidence: Limited. 3 human studies found in our search.
What has been studied
| Who or what was studied | What was found, and the catch | Source |
|---|---|---|
| Systematic review n = 36 studies, 1 human | Of 36 studies, 35 were in animals, where healing of tendon, ligament, muscle and bone improved. The one human study was small and retrospective. Limit: Review says plainly: no clinical safety data exist for BPC-157. | Vasireddi 2025 PMID 40756949 |
| Small human study n = 16 people | Patients given BPC-157 for knee pain mostly said they felt better when phoned months later. Limit: No control group, no imaging, relies on memory by phone. | Lee 2021 PMID 34324435 |
| Small human study n = 12 people | Women with stubborn bladder pain reported big improvements after BPC-157; no side effects were reported. Limit: Twelve people, one clinic, no comparison group, self-reported outcome. | Lee 2024 PMID 39325560 |
| Review | Rodent studies suggest faster healing of tendon, ligament and muscle. Limit: Animal data only; not confirmed in people. | Gwyer 2019 PMID 30915550 |
| Review | Describes proposed ways BPC-157 might help wounds heal, such as nitric oxide signaling and new blood vessels. Limit: Mechanisms come from rat models. | Seiwerth 2021 PMID 34267654 |
| Animals | Rat tendon cells in a dish grew out and moved more with BPC-157. Limit: Cells only. | Chang 2011 PMID 21030672 |
| Small human study n = 2 people | Two adults showed no change in heart, liver, kidney, thyroid or sugar markers after BPC-157. Limit: Two people. Far too few to call anything safe. | Lee 2025 PMID 40131143 |
| Review | Broad activity in animal injury models, but not approved for human use anywhere for lack of clinical data. Limit: Narrative and patent review. | Józwiak 2025 PMID 40005999 |
Safety signals in the studies
- Systematic review: animal studies show no harm across organs, but there is no human safety data. PMID 40756949
- No adverse events in a 12-person pilot. PMID 39325560
- Animal studies show no harm across organs; no human safety data. PMID 40756949
- Placed on the World Anti-Doping Agency prohibited list in 2022; unapproved by regulators. PMID 40005999
- No biomarker changes in a two-person pilot. PMID 40131143
Most cited author in this list: Lee, 3 of 8 sources. When a small number of groups produce most of the evidence, independent replication is thinner than the source count suggests.
Where it stands with regulators
- BPC-157 appears on FDA's list of bulk drug substances nominated for compounding and then withdrawn, under the heading Bulk drug substances nominated but withdrawn. FDA's stated concern: possible immune reactions for certain routes of administration, plus complexities with peptide related impurities and active ingredient characterization, and FDA says it lacks sufficient information to know whether the drug would cause harm in humans. Page content current as of 04/22/2026, checked 08-26-2026. Source
- A 2025 systematic review of 36 studies on BPC-157 states that no clinical safety data exist for it and that it is not approved by any regulator. Checked 08-26-2026. Source
- A separate 2025 review states BPC-157 is unapproved by the FDA or any other regulator for lack of clinical data, and notes it was placed on the World Anti-Doping Agency prohibited list in 2022. Checked 08-26-2026. Source
What is missing
A 2025 systematic review of 36 studies says plainly that no clinical safety data exist for BPC-157. The human reports that do exist are small, 16 and 12 people, uncontrolled, and one relies on memory recalled over the phone. The only human safety check was a two-person pilot, far too small to draw a conclusion from. No regulator anywhere has approved it.
Clinician commentary (YouTube)
This is commentary, not evidence. 4 clinicians with large audiences discuss this on camera. Each video below is summarized in our words and linked so you can watch the source yourself. Any amounts mentioned are what the named clinician says on camera, not PeptideGauge guidance. The graded studies above remain the record of what is known. How this layer works.
Dr. Alex Tatem
In “BPC-157 & TB-500: The Truth About the Wolverine Stack”, Dr. Alex Tatem discusses BPC-157. What he says, in short:
- He explains BPC-157 is body protection compound 157, a 15 amino acid synthetic peptide derived from a protein in human gastric juice, discovered by Dr. Predrag Sikiric's group in Zagreb starting in the late 1980s.
- He says the rodent preclinical data is impressive across nearly every tissue (GI ulcers, tendons, muscle, bone, skin, nerve, brain), working through several pathways including nitric oxide and eNOS, VEGFR2 driven angiogenesis, ERK1/2, and FAK/paxillin signaling in tendon fibroblasts.
- He says human evidence is thin: unpublished phase 2 trials for ulcerative colitis and multiple sclerosis, an uncontrolled unblinded 2024 pilot of 12 women with interstitial cystitis where 10 of 12 reported full symptom resolution, and a small uncontrolled knee injection case series, none of it methodologically solid.
- He flags that over 80% of the published BPC-157 literature comes from a single research group, which he says is a real publication bias concern even though it isn't disqualifying.
- On safety he says animal studies found no lethal dose in mice, rats, rabbits or dogs, just mild injection site irritation, but he raises a theoretical cancer concern because BPC-157 promotes angiogenesis, while stressing there is no evidence it actually causes cancer.
- He notes it can survive gastric acid for over 24 hours so it works orally at microgram per kilogram doses, but injectable half life is under 30 minutes with only 14 to 19% intramuscular bioavailability in rats, and there is no established human dose.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.
In “The Truth About Popular Peptides (What Works, What’s Overhyped) | Peptide Tier List pt.1”, Dr. Alex Tatem discusses BPC-157. What he says, in short:
- He says BPC-157 (body protection compound 157) comes from a peptide naturally found in gastric juice, first isolated in dogs, and is meant to speed up the body's natural healing.
- He says in vitro it makes fibroblasts, the cells that repair wounds, organize more efficiently, but he notes there are no good human clinical trials, only benchtop and animal data.
- He says anecdotal reports swing wildly, from people claiming it cured spinal stenosis and let them avoid back surgery to others calling it sugar water that did nothing.
- He says he hasn't seen serious side effects from BPC-157 itself, aside from possible contamination or heavy metals from gray market sources.
- He gives BPC-157 a C tier rating overall, based on the mixed reports plus its general safety.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.
1 more video where Dr. Alex Tatem covers BPC-157
In “Every Popular Peptide Ranked | GLP-1, Growth Hormone, HCG, NAD+, IGF-1, Peptide Tier List”, Dr. Alex Tatem discusses BPC-157. What he says, in short:
- He says BPC-157 is derived from gastric juice and meant to speed the body's natural healing, and that in vitro it helps fibroblasts organize more efficiently, but human clinical trials are lacking.
- He notes anecdotal reports range from claims it helped someone avoid back surgery for spinal stenosis to reports it did nothing, complicated by people often stacking it with TB-500 or GHK-Cu.
- He says he hasn't seen serious side effects reported, aside from gray market contamination risk, and gives BPC-157 a C tier ranking.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.
Dr. Ashley Froese
In “Doctor Explains PRP vs BPC-157 - Healing SHOWDOWN”, Dr. Ashley Froese discusses BPC-157. What she says, in short:
- She says BPC-157 is a peptide fragment of "body protecting compound," a substance found in gastric juices whose main job seems to be protecting the gut and speeding healing.
- She says the evidence for its healing effects comes from animal studies only, there is no human data, so she cannot prescribe it or make claims about how it works in people.
- She notes it is not FDA approved and sits in a gray area, sold online only as a research peptide, not for human consumption.
- She says it works for some people and some injuries but not for everyone, and that genetics and the nature of the injury heavily affect the outcome.
- She says she does not dismiss it, has met people it changed for the better, has tried it herself, and would try it again, though as a doctor she will not recommend it.
- She contrasts it with platelet rich plasma, which she says has real human data behind it and is something she can actually offer patients, unlike BPC-157.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.
In “I Talked to 100 People on PEPTIDES - Here's What They Said”, Dr. Ashley Froese discusses BPC-157. What she says, in short:
- She calls the BPC-157 plus TB-500 combo the "Wolverine stack" and says for a long time she was lukewarm on it, since it has not worked for roughly half the people she has talked to.
- She describes a patient with torn ligaments who did PRP then BPC-157 and TB-500, against a one year expected recovery he was out of his brace and bearing weight, feeling about 75% healed at 6 weeks.
- She mentions two CrossFitters with wrist pain who started BPC-157 and TB-500 and had the pain gone within a couple of days.
- She explains BPC-157 comes from "body protecting compound" in the gut, believed to support cell turnover and protect the stomach lining, which is why people try it for gut health.
- She relays a case of someone using oral BPC-157 with oral KPV and injectable GHK copper who said three years of gut inflammation felt gone within a week, and another person whose chronic heartburn cleared using oral BPC-157.
- She notes injectable BPC-157 currently cannot legally be compounded for human use, while oral BPC-157 can be sold as a supplement.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.
4 more videos where Dr. Ashley Froese covers BPC-157
In “Dr. Reveals What Really Happened at the FDA Meeting on Peptides”, Dr. Ashley Froese discusses BPC-157. What she says, in short:
- She says she attended the FDA's two-day pharmacy compounding advisory committee meeting and that BPC-157 was the day's biggest topic, with a six hour debate.
- She says the FDA appeared to have reviewed very little research on BPC-157 and used that thin evidence to argue the case against it.
- She says physicians and peptide representatives submitted real-world human studies to the docket, but the FDA said they hadn't had time to review them and never passed them to the committee.
- She says the FDA leaned on just the abstract of one controlled human study and on three FAERS adverse event reports, out of what she says are millions of known uses of BPC-157.
- She says the FDA also raised concerns from dog and rat studies showing raised liver enzymes and lower PTT, but says the doses used in those animal studies were far higher than doses people and physicians actually use.
- She says the committee ultimately voted to override the FDA and recommend BPC-157, and describes the room's energy as high right after that vote.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.
In “Dr Admits - I Was WRONG About The Wolverine Stack”, Dr. Ashley Froese discusses BPC-157. What she says, in short:
- She describes BPC 157 as a 15 amino acid fragment of body protection compound, naturally found in human gastric juice, discovered by researchers in the 1970s studying why the stomach lining heals so fast.
- She says animal research shows accelerated healing well beyond the gut, in tendons, ligaments, muscle, nerves, intestinal reconnection surgeries, and toxic liver injury.
- She calls it a healing traffic controller that helps inflammation, blood flow, and repair signals happen in the right sequence, comparing it to a foreman at a construction site.
- She says BPC 157 is unusually stable and survives gastric acid, which is why it can be taken orally, and says she personally feels comfortable suggesting an oral version in certain cases.
- She says there is currently no evidence BPC 157 causes or feeds cancer, though she flags that because it promotes new blood vessel growth, someone with an active tumor should be cautious.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.
In “The FDA Is About to Decide the Future of Peptides: BPC-157, TB-500, KPV, & MOTS-C”, Dr. Ashley Froese discusses BPC-157. What she says, in short:
- She says the FDA is specifically reviewing it for its ability to treat or heal ulcerative colitis.
- She says she has personally never talked to anyone who used it for ulcerative colitis with success, but has seen it used orally for gastric reflux, gastritis, and other IBS related gut symptoms.
- She describes it as a stable fragment of a compound the stomach makes, called body protection compound, which is why it can be taken orally.
- She says it is believed to trigger angiogenesis, new blood vessel formation, to help heal injured tissue, and to sensitize an area to signal that healing needs to happen.
- She says people use it for soft tissue repair such as strains, sprains, and arthritis, along with the gut symptoms she described.
- She says she has used it herself shortly after surgeries and PRP injections, and thinks its potential to help is bigger when used during an acute healing window.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.
In “Real Doctor: If I Started Peptides Today, I'd Do THIS (The Ultimate Peptide Roadmap)”, Dr. Ashley Froese discusses BPC-157. What she says, in short:
- In her roadmap, she places BPC 157 in the repair step, after weight loss, energy, and sleep and recovery have already been addressed.
- She describes it as a peptide that shines a spotlight on injured tissue, improving blood flow to the area and signaling the body to heal it.
- She pairs it with TB 500 as the Wolverine blend, but notes there is nothing stopping someone from starting it earlier if they want.
- She says these peptides are systemic, so injecting at the injury site is not required, and she prefers injecting where blood flow is high.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.
Dr. Craig Koniver
Dr. Craig Koniver does not run a channel of his own. Each video below is an interview published by the show that recorded it.
In “Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver” on Andrew Huberman, Dr. Craig Koniver discusses BPC-157. What he says, in short:
- He calls BPC-157 the most utilized peptide in his practice and says they liked to use it with almost every patient because it is very anti-inflammatory.
- He says it is a naturally occurring gut peptide, which is why oral forms survive the gut when most peptides taken orally are broken down.
- He says that in his clinical observation, with thousands upon thousands of patients, inflammation came down so people felt less stiff and sore and their knees and shoulders improved.
- He describes a clinic range that started at about 500 micrograms a day and worked up to about 5,000 micrograms a day, on a protocol of five days on and two days off.
- He says he expected oral BPC to be best for gut problems but observed that injecting it subcutaneously worked better even for gastrointestinal issues.
- He says injection site does not matter because it works systemically, so an abdominal or glute injection still benefits an injured elbow and every other joint.
- He says he thinks it shines most in ligaments and tendons, and notes that unlike steroids it can be injected directly into a tendon, sometimes mixed with PRP or PRF.
- He says he has not seen side effects from it and is concerned that with compounding pharmacies cut off since the FDA's October 2023 category 2 listing, people will turn to gray and black market sources that may contain LPS and other contaminants.
so I think with bpc for me kind of the most utilized peptide that we've used so we'd like to use bpc almost with every patient it is very anti-inflammatory
you can inject it in your abdomen or your rear end you're still going to get benefit in your elbow
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Dr. Craig Koniver - The Godfather of Peptides | SRS #330” on Shawn Ryan Show, Dr. Craig Koniver discusses BPC-157. What he says, in short:
- He puts BPC-157 in the anti-inflammatory category of peptides and says the name stands for body protection compound.
- He says it is very anti-inflammatory to soft tissue, specifically tendons and ligaments, and describes it as coming from stomach juices.
- He explains the mechanism as helping clear aggregated inflammatory cells and cytokines out of the tissue and extracellular space so they stop irritating nerves, which he frames as actually healing rather than masking.
- He describes giving a patient with a messed up forearm intravenous BPC in the office and says that patient reported being 100 percent better after two treatments.
- He says that given how much people who train get tight and injury-prone, you could argue someone who works out a lot should be on BPC-157 all the time.
- He addresses the angiogenesis and cancer concern by saying it does not resonate with him, that in more than ten years and big numbers of patients he has never seen cancer develop, and that new blood vessel growth can equally be framed as helpful in heart disease.
- He says he is biased toward the clinical side and will not dismiss anecdotal data just because it did not come from a formal study.
- He says his clinic uses only compounded material from FDA registered, state board inspected pharmacies and no research chemicals, and blames the FDA's compounding removal for the growth of the unsupervised gray market.
It's very anti-inflammatory to the soft tissue. So the tendons and ligaments
Has I've ever seen cancer develop? No, you know, and we're talking big numbers of people now.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
3 more videos where Dr. Craig Koniver covers BPC-157
In “Is Peptide Therapy the Future of Medicine? | Dr. Craig Koniver” on The Ancient Health Podcast, Dr. Craig Koniver discusses BPC-157. What he says, in short:
- He says BPC stands for body protection compound and that it grew up as an anti-inflammatory peptide.
- He says what is also really cool about it is that it upregulates growth hormone receptors, so pairing it with ipamorelin or tesamorelin works both sides of the equation and gives more efficiency.
- He calls it probably the best peptide for someone with leaky gut, and pairs it with thymosin alpha-1 for immune and gut cases.
- He says that although people take BPC orally, he has found that in his opinion subcutaneous injection affects the gut better and gives better gut results than the oral form.
- He describes BPC as one of the four he reaches for in the immune and inflammation group, alongside thymosin alpha-1, KPV and GHK copper.
- He says his clinic combines it with other peptides in one prefilled, pH tested and potency tested solution so patients are not injecting several things separately.
bpc very anti-inflammatory it's known for helping in the gut like you mentioned if someone's got leaky gut probably the best peptide is bpc
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Dr. Craig Koniver: Health Optimization with Peptides, Light Therapy, and Methylene Blue” on Health Optimization Medicine Podcast, Dr. Craig Koniver discusses BPC-157. What he says, in short:
- He calls BPC-157 the most versatile peptide his clinic uses and says it is potently anti-inflammatory.
- He says it seems to have no ceiling, so they can use very large dosages.
- He describes giving it intravenously as a spark when someone comes in with an injured knee or shoulder and a lot of inflammation, and says it does help people feel better.
- He says the IV dose is a starting point and that the lasting benefit comes from subcutaneous BPC done once or twice a day over time.
- He says it can be used subcutaneously, orally, topically and intravenously, and that they get really good results across those routes.
- He lists what he sees it help with as skin, psoriasis, gut and joints, generally in combination with other things.
- He says using it is a choice rather than a dependency, and that people who have used peptides for years are not dependent on them.
I think the most versatile peptide we use is BPC-157, body protection compound. Potently anti-inflammatory, seemingly no ceiling.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Episode 95: Dr. Craig Koniver - Founder of Koniver Wellness, Performance Medicine Expert” on Habits & Hustle w/ Jennifer Cohen, Dr. Craig Koniver discusses BPC-157. What he says, in short:
- He puts BPC-157 in the anti-inflammatory group of peptides and says BPC stands for body protection compound.
- He says it is anti-inflammatory and good for the gut lining.
- He says it is also good for protecting ligaments and tendons, which he says is where a lot of people actually get injured.
- He says that because his clinic sees athletes at various competition levels, you could argue those athletes should be on BPC all the time as protection.
- He says his clinic stacks peptides rather than using them one at a time, sometimes three, four, seven or nine at once, based on his observations of what works.
- He says they prefill syringes for clients so people are not drawing up and injecting several peptides a day, which he says most practices do not do.
it's anti-inflammatory good for the gut lining but also good for protecting the ligaments and tendons
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
Dr. Jones, DC
In “What Science ACTUALLY Says About BPC-157 Benefits, Dosing & Side Effects (Doctor Reveals Truth)”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He says BPC-157 stands for body protection compound and that the stomach makes a version of it to protect and heal the gut lining from acid.
- He describes the main mechanism as angiogenesis, comparing new blood vessels to building highways that deliver healing supplies into an injured area.
- He says the growth factor research is largely animal data and openly concedes there is not as much human research as he would like.
- He contrasts it with NSAIDs and cortisone, saying those suppress the healing response while this works with the body's own pathways.
- He describes clinic starting points of 500 micrograms daily for acute injuries under two weeks old, 250 micrograms daily for the first two weeks after surgery, and 750 micrograms daily for people whose earlier cycles failed, framed as what his practitioners found rather than published dosing.
- He addresses the cancer question as theoretical, saying angiogenesis could in principle feed a tumor, and states that in ten years of clinic use he has not seen a case he could link to peptide use while conceding that is clinical experience and not a controlled study.
- He says his clinic will not treat anyone with active cancer or a cancer history without oncology clearance, and lists pregnant women, children, and active infections as other exclusions.
- He describes cycling 3 to 4 months on with 1 to 2 months off, saying continuous use causes a critical decrease in effectiveness.
BPC57 stands for body protection compound.
there's no official human dosing in the research yet
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Doctor Reacts to Most Powerful Peptide Stacks (GLOW, KLOW & Wolverine)”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He says BPC-157 stands for body protection compound and accelerates tissue repair by stimulating angiogenesis, which he explains as more blood flow and nutrients reaching injured tissue.
- He says it also has gut healing properties and that patients with leaky gut, ulcers, or inflammatory bowel issues may have the intestinal lining repaired, framed as what he sees in his clinic.
- He describes about 500 micrograms daily as the amount used inside the GLOW protocol his clinic runs.
- He says the version he trusts is prescribed through a 503A compounding pharmacy, and that he has seen infections from contaminated peptides and zero results from vials that were underdosed or fake.
- He says gray market certificates of analysis mean little because the same vendors are already labeling products not for human consumption.
This peptide actually accelerates tissue repair. It stimulates angioenesis, which is the formation of new blood vessels.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
8 more videos where Dr. Jones, DC covers BPC-157
In “This Peptide Stack Prevents or Fixes Ozempic Face Fast! (Doctor Explains)”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He calls BPC-157 the localized repair player within the GLOW stack.
- He says the research shows it supporting blood vessel formation and tissue healing right where it is applied.
- He describes its job in this stack as getting the local environment ready so the GHK-Cu collagen signal has healthy tissue to work on.
- He says it and TB-500 are not redundant and work on different parts of the same job.
- He says the BPC-157 plus TB-500 pairing is what he always calls the Wolverine.
BPC-157 is the localized repair player
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Doctor Explains GHK-Cu the Glow & Grow Peptide”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He calls BPC-157 the gut and connective tissue specialist of the GLOW stack.
- He says it is phenomenal at healing the lining of the stomach and repairing tendons and ligaments.
- He says it does not signal collagen and elastin for skin and does not regrow hair.
- He says it is not running the broad genetic repair program he attributes to the copper peptide.
- He says none of these peptides work in a vacuum, that they amplify a strong foundation, and that they do almost nothing without one.
BBC57 is your gut and connective tissue specialist.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Doctor Explains How the FDA Vote Changes BPC-157, TB-500, KPV & MOTS-c”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He says an FDA advisory committee voted on BPC-157 for the 503A bulk list and that approval was never on the table, contradicting vendor emails claiming the FDA approved it.
- He says the committee voted yes eight to six with one abstention on every compound it got through, but that the FDA told the room in advance a yes would still not mean FDA approval, would not require a label telling patients how to use it, and would not require current good manufacturing practices.
- He says the entire evidence file handed to the committee was two unpublished studies, one following about 66 people reporting less pain and better function at a month with no control group, and one of 40 meniscus surgery patients that found no statistically significant difference at six months and a year.
- He says the FDA told the room that BPC-157 is a common name rather than a recognized chemical name, and that it had encountered multiple chemical forms and in some cases a different active ingredient sold under that same name.
- He says the nomination paperwork was internally inconsistent, with chemical name, formula, and weight pointing to one form while the certificate of analysis described another, which is why each compound was voted on twice.
- He relays blind testing presented to the committee in which five BPC-157 products were tested, one came within 10 percent of its label, most were stronger than labeled, and one contained no BPC-157 at all.
- He flags that the man who commissioned that testing manufactures ingredients domestically, has a direct commercial interest, and did not disclose his methodology, and says unchallenged is not the same as verified.
- He says every objection was about documentation, naming, and manufacturing rather than any finding that the compounds hurt people, and that he now has no date for resolution after previously guessing late 2026 or early 2027.
BBC 157 is a common name. It is not a recognized chemical name.
Five products tested, one came in within 10% of what the label said.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “The Hidden Peptide Stack That Doubles Your GLP 1 Results for Autoimmune & Inflammatory Conditions”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He calls BPC-157 his favorite peptide for inflammation and says animal models suggest it works systemically, with what he calls emerging human evidence.
- He says animal research points to reduced tissue level inflammation, new blood vessel formation, better nutrient delivery to damaged tissue, and repair of gut barrier dysfunction.
- He states plainly that human clinical trials are still limited while calling the preclinical evidence very compelling.
- He describes recommending the oral form at about 500 micrograms per day, on the reasoning that oral dosing gives first pass contact with the gut barrier.
- He says patients his doctors prescribe it to often report gut symptom improvement, and that he also sees joint pain and injuries improve, with many noticing change within four to six weeks, which he presents as clinic observation.
- He says to avoid it with cancer or any history of cancer because it may promote cell tissue growth, including potentially problematic cells.
- He places it as a layered addition around weeks four to eight, after a GLP-1 medication and low dose naltrexone are already in place.
BPC-157 is my favorite peptide for inflammation because research and animal models suggest that it works systemically.
I recommend the oral about 500 micrograms per day.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Doctor Explains Every Fat Loss Miracle Peptide in Detail (for Women and Men)”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He frames BPC-157 as an inflammation tool rather than a fat loss compound, arguing chronic inflammation has to be addressed before fat loss will move.
- He says it provides a systemic anti-inflammatory effect with gut healing and tissue repair, and that it heals the gut lining to reduce inflammation coming from leaky gut.
- He says it enhances recovery so patients can train harder and reduces inflammatory markers that impair insulin sensitivity.
- He recounts a patient with undiagnosed Hashimoto's whose inflammation and thyroid antibodies dropped and whose weight loss resumed within eight weeks after low dose naltrexone, BPC-157, KPV, and a flexible carnivore diet were added, which he presents as a clinic case.
- He says he uses BPC-157 with KPV and low dose naltrexone when patients show high inflammatory markers, gut issues, autoimmune conditions, or non-autoimmune inflammatory conditions such as PCOS or menopause.
It ends up healing the gut lining, reducing systemic inflammation from leaky gut issues where toxins leak through the damaged gut walls and your into your bloodstream.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “What Are Peptides AND Are They Safe? (Doctor Explains Risk & Rewards of Peptides)”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He says BPC stands for body protection compound and that the body is already making a version of it in the gut.
- He describes injecting it as sending a construction crew directly to the injury site and says it turns on the body's own healing signals rather than forcing an effect.
- He says patients with chronic tennis elbow, rotator cuff problems, and knee issues have told him within four to six weeks on a BPC-157 and TB-500 cycle that they forgot they had the problem, which he presents as clinic stories while saying he wants the human clinical data.
- He says a research chemical version might be completely inactive and that the results he describes come from 503A pharmacy material.
- He recounts a PCOS patient whose GLP-1 dose was reset downward and who had BPC-157 added for inflammation alongside thyroid optimization and a large increase in food intake, framed as a clinic case.
- He says high cortisol can block peptide function outright and that someone can inject all the BPC-157 they want and still not heal under chronic stress.
BPC stands for body protection compound. Your body's actually making a version of this right now in your gut.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Doctor Reveals The 10 Most POWERFUL Peptide Stacks (Science Backed Peptides)”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He says BPC-157 is derived from a compound found naturally in gastric juices and that it protects the gut lining.
- He says animal studies show consistent tissue healing effects across multiple tissue types, and that patients his doctors prescribe it to commonly report accelerated healing of tendons, ligaments, and muscle tissue.
- He says it promotes angiogenesis, which he explains as new blood vessel growth, and that this is exactly why better healing would be expected.
- He describes around 500 micrograms per day, sometimes split into two 250 microgram doses, which he says may improve healing further.
- He says the injectable form works better for musculoskeletal injuries while the oral form suits gut issues such as IBS, leaky gut, and digestive problems, at 1 to 2 pills daily of 500 micrograms each.
- He says cycles run anywhere from 1 to 6 months with a break in between.
Dosing for BBC57 usually around 500 micrograms per day. You can split it up say 250 250 to potentially improve healing even more.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Doctor Explains How to CORRECTLY Inject & Dose Peptides (not what you think)”, Dr. Jones, DC discusses BPC-157. What he says, in short:
- He says he runs BPC-157 and TB-500 himself for knees that would be wrecked after volleyball tournaments.
- He walks a viewer's actual numbers on camera: a 5 milligram vial with 2 milliliters of water and a target of 250 micrograms, which he works out to 10 units on a 100 unit insulin syringe.
- He says the sanity check is asking how many shots the vial should give, and that this example should yield about 20 doses, so a calculator returning 100 units would empty it in two.
- He says the common shorthand that 10 units equals 1 milligram is only true for one vial mixed one particular way and stops being true the moment the water volume changes.
- He says a unit measures liquid while milligrams and micrograms measure peptide, so telling him a unit count carries no clinically relevant information on its own.
- He says he coaches people to choose their water volume so the dose lands between 5 and 10 units where it can actually be read on the syringe.
- He says when someone tells him a peptide did nothing, the compound is not the first thing he suspects, because every failure point between powder and bloodstream is silent.
5 mg vial, 2 ml of water. The target dose he was looking for was 250 micrograms.
So, he needs a tenth of a hundred units, ten units.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
Common questions
Is BPC-157 approved by the FDA?
No. It is not approved by the FDA or by any other regulator. It is on FDA's list of bulk drug substances that were nominated for compounding use and then withdrawn.
What has BPC-157 actually been tested for in people?
Small, uncontrolled human reports. One followed 16 people with knee pain by phone months later, and most said they felt better. Another followed 12 women with stubborn bladder pain who reported improvement, with no comparison group. A separate two-person pilot checked standard blood markers and found no change.
Is there real human safety data for BPC-157?
A 2025 systematic review of 36 studies states plainly that no clinical safety data exist for BPC-157. The only human safety check found was a two-person pilot, far too small to draw any conclusion from.
Why are so many studies cited for it?
Because there genuinely are many studies of BPC-157, but a 2025 systematic review found that of 36 studies, 35 were done in animals, mostly rats, testing tendon, ligament, muscle and bone healing. Only one was in humans, and it was small and retrospective.
Is BPC-157 banned in sports?
Yes. It has been on the World Anti-Doping Agency prohibited list since 2022, and a 2025 review notes this alongside its unapproved status.
What is BPC-157 copied from?
A fragment of a protein found in human stomach fluid. The version sold is made in a lab, not extracted from the body, and has not been shown to behave the same way the natural protein does.
Will this page tell me how much BPC-157 to use?
No. We do not publish amounts or schedules for any peptide. That decision belongs with a licensed doctor.
Sources
- Chang (2011). PMID 21030672
- Gwyer (2019). PMID 30915550
- Józwiak (2025). PMID 40005999
- Lee (2021). PMID 34324435
- Lee (2024). PMID 39325560
- Lee (2025). PMID 40131143
- Seiwerth (2021). PMID 34267654
- Vasireddi (2025). PMID 40756949
BPC-157 appears on the FDA list of bulk drug substances nominated for compounding and then withdrawn, under the heading Bulk drug substances nominated but withdrawn, over concerns about immune reactions, peptide related impurities and insufficient safety information. It is not an FDA-approved drug and has been on the World Anti-Doping Agency prohibited list since 2022. Checked 08-26-2026.
Want these studies next to every other one on the site?
Open the evidence tableMixing a vial? Do the math with the calculator.
Open the calculator